Skip to main content
ImmuneCited

Processus de recherche

333 figures issues de recherches évaluées par des pairs

Tous Vitamin D Zinc Iron Andrographis Astragalus Elderberry Pelargonium sidoides Cordyceps Arginine N-Acetylcysteine Quercetin Curcumin Glutathione Resveratrol Astaxanthin Omega-3 Fatty Acids (EPA/DHA) Conjugated Linoleic Acid
All Types Chart Diagram Photograph Flowchart Forest Plot Micrograph Other
Figure 4
Figure 4 Diagram

Diagram illustrating the key biological concepts related to curcumin Modulation of the Gut, synthesizing evidence presented in the study.

Curcumin Modulation of the Gut-Brain Axis for Neuroinflammation and Metabolic Disorders Prevention …

Figure 5
Figure 5 Diagram

Illustrative overview of the mechanisms involved in curcumin Modulation of the Gut, depicting key molecular and cellular pathways.

Curcumin Modulation of the Gut-Brain Axis for Neuroinflammation and Metabolic Disorders Prevention …

Figure 4. The Keap1-NRF2 pathway. Under normal conditions, Keap1 behaves as a negative regulator of NRF2, preventing its activation and thereby inhibiting its antioxidant response. Keap1 binds to
Figure 6 Diagram

The Keap1-NRF2 pathway. Under normal conditions, Keap1 behaves as a negative regulator of NRF2, preventing its activation and thereby inhibiting its antioxidant response.

Curcumin Modulation of the Gut-Brain Axis for Neuroinflammation and Metabolic Disorders Prevention …

Figure 5. Anti-inflammatory effects of curcumin: molecular and clinical evidence. Image shows the main mechanisms by which curcumin exerts anti-inflammatory effects both systemically and in adipocytes. At the molecular level, curcumin blocks inflammatory signa
Figure 7 Diagram

Anti-inflammatory effects of curcumin: molecular and clinical evidence. Image shows the main mechanisms by which curcumin exerts anti-inflammatory effects both systemically and in adipocytes.

Curcumin Modulation of the Gut-Brain Axis for Neuroinflammation and Metabolic Disorders Prevention …

Figure 1
Figure 1 Diagram

Conceptual diagram summarizing the relationship between modulating Ferroptosis in Aging: The Therapeutic Potential of Natural Products and the biological processes described in this research.

Modulating Ferroptosis in Aging: The Therapeutic Potential of Natural Products.

Figure 2
Figure 2 Diagram

Visual summary of the pathways and interactions relevant to modulating Ferroptosis in Aging: The Therapeutic Potential of Natural Products, as discussed in the context of aging is a multifactorial process driven by accumulating cellular damage.

Modulating Ferroptosis in Aging: The Therapeutic Potential of Natural Products.

Figure 3
Figure 3 Diagram

Schematic representation highlighting the mechanisms underlying modulating Ferroptosis in Aging: The Therapeutic Potential of Natural Products and their potential therapeutic implications.

Modulating Ferroptosis in Aging: The Therapeutic Potential of Natural Products.

Longevity
Figure 16 Chart

Experimental results examining modulating Ferroptosis in Aging: The Therapeutic Potential of Natural Products, with data points illustrating key findings related to aging is a multifactorial process driven by accumulating cellular damage.

Modulating Ferroptosis in Aging: The Therapeutic Potential of Natural Products.

Figure 1
Figure 1 Diagram

Conceptual diagram summarizing the relationship between the use of oral and enteral tube and the biological processes described in this research.

The use of oral and enteral tube-fed arginine supplementation in pressure injury …

Figure 3
Figure 3 Chart

Measured parameters from a study evaluating astragaloside IV suppresses histamine, contributing to the overall assessment of allergic rhinitis (AR) is a symptomatic allergic disease that leads to severe inflammation.

Astragaloside IV suppresses histamine-induced inflammatory factors and mucin 5 subtype AC overproduction …

Figure 4
Figure 4 Chart

Graphical representation of outcomes in a study of astragaloside IV suppresses histamine, highlighting trends observed across experimental conditions.

Astragaloside IV suppresses histamine-induced inflammatory factors and mucin 5 subtype AC overproduction …

Figure 5
Figure 5 Chart

Quantitative data from a study on astragaloside IV suppresses histamine, presenting measured outcomes relevant to the investigation of allergic rhinitis (AR) is a symptomatic allergic disease that leads to severe inflammation.

Astragaloside IV suppresses histamine-induced inflammatory factors and mucin 5 subtype AC overproduction …

Figure 6
Figure 6 Chart

Experimental results examining astragaloside IV suppresses histamine, with data points illustrating key findings related to allergic rhinitis (AR) is a symptomatic allergic disease that leads to severe inflammation.

Astragaloside IV suppresses histamine-induced inflammatory factors and mucin 5 subtype AC overproduction …

Figure 7
Figure 7 Chart

Statistical analysis from research investigating astragaloside IV suppresses histamine, comparing treatment groups and control conditions.

Astragaloside IV suppresses histamine-induced inflammatory factors and mucin 5 subtype AC overproduction …

Figure 8
Figure 8 Chart

Measured parameters from a study evaluating astragaloside IV suppresses histamine, contributing to the overall assessment of allergic rhinitis (AR) is a symptomatic allergic disease that leads to severe inflammation.

Astragaloside IV suppresses histamine-induced inflammatory factors and mucin 5 subtype AC overproduction …

Figure 9
Figure 9 Chart

Graphical representation of outcomes in a study of astragaloside IV suppresses histamine, highlighting trends observed across experimental conditions.

Astragaloside IV suppresses histamine-induced inflammatory factors and mucin 5 subtype AC overproduction …

Figure 1
Figure 1 Chart

Experimental results examining early intervention with Kan Jang® to treat upper, with data points illustrating key findings related to BACKGROUND AND AIM: Andrographis paniculata and Eleutherococcus senticosus preparations and their fixed combination, .

Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, …

Figure 2
Figure 2 Chart

Statistical analysis from research investigating early intervention with Kan Jang® to treat upper, comparing treatment groups and control conditions.

Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, …

Figure 3
Figure 3 Chart

Measured parameters from a study evaluating early intervention with Kan Jang® to treat upper, contributing to the overall assessment of BACKGROUND AND AIM: Andrographis paniculata and Eleutherococcus senticosus preparations and their fixed combination, .

Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, …

Figure 4
Figure 4 Chart

Graphical representation of outcomes in a study of early intervention with Kan Jang® to treat upper, highlighting trends observed across experimental conditions.

Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, …

Figure 5
Figure 5 Chart

Quantitative data from a study on early intervention with Kan Jang® to treat upper, presenting measured outcomes relevant to the investigation of BACKGROUND AND AIM: Andrographis paniculata and Eleutherococcus senticosus preparations and their fixed combination, .

Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, …

Figure 6
Figure 6 Chart

Experimental results examining early intervention with Kan Jang® to treat upper, with data points illustrating key findings related to BACKGROUND AND AIM: Andrographis paniculata and Eleutherococcus senticosus preparations and their fixed combination, .

Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, …

Figure 7
Figure 7 Chart

Statistical analysis from research investigating early intervention with Kan Jang® to treat upper, comparing treatment groups and control conditions.

Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, …

Figure 8
Figure 8 Chart

Measured parameters from a study evaluating early intervention with Kan Jang® to treat upper, contributing to the overall assessment of BACKGROUND AND AIM: Andrographis paniculata and Eleutherococcus senticosus preparations and their fixed combination, .

Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, …

Page 9 sur 14